












Serial No. 09/131,385



wherein Z is selected from the group consisting of hydrogen, alkali metal ion, and amine;
and pharmaceutically acceptable salts thereof.

9. A compound according to claim 8, wherein said compound is selected from the group consisting of:



wherein Y is a phosphono protecting group.




Handwritten: Rule 1260 12.

A process for preparing a compound of claim 4, comprising:


removing a phosphono protecting group from a compound according to one of the following formula:

Serial No. 09/131,385


+T70710



Cyclosporin A



and



wherein Y is the phosphono protecting group; and
recovering the product.

Please add the following claims:

Rule 23 *126* *15-20* ~~--32.~~ A pharmaceutical composition comprising an effective anesthetic amount of the compound according to any one of claims ~~24-29~~ and a pharmaceutically acceptable carrier.--

24 *14-20* ~~--33.~~ A method of producing an anesthetic effect which comprises administering to a patient in need thereof an effective anesthetic amount of the compound according to any one of claims ~~23-29~~.

C5 *D* *25* *1-5, 8, 9 or 10* ~~--34.~~ A pharmaceutical composition comprising an effective anti-cancer amount of the compound according to any one of claims ~~1-10~~ and a pharmaceutically acceptable carrier, wherein said pharmaceutical compound is etoposide.--